Literature DB >> 19374605

Desmoid tumors: need for an individualized approach.

Eelco de Bree1, Ronald Keus, John Melissas, Dimitris Tsiftsis, Frits van Coevorden.   

Abstract

Desmoid tumor, also known as aggressive fibromatosis or desmoid-type fibromatosis, is a rare monoclonal, fibroblastic proliferation arising in musculoaponeurotic structures. Although histologically benign, desmoids are often locally invasive and associated with a high local recurrence rate after resection. Since it is a heterogeneous disease, in particular regarding clinical presentation, anatomic location and biological behavior, treatment should be individualized to reduce local tumor control failure with concurrently acceptable morbidity and preservation of quality of life. Many issues regarding optimal treatment of desmoids remain controversial. However, wide surgical excision remains the treatment of choice, except when surgery is mutilating and is associated with considerable function loss or major morbidity. Involvement of surgical margins is probably associated with an increased risk of local recurrence. Postoperative radiotherapy results in a significant reduction of the local recurrence rate, but only in the case of involved surgical margins. Radiotherapy for gross disease is considerably effective, but is associated with a relatively high rate of complications, which are usually mild or moderate and radiation dose dependent. Radiotherapy should only be applied where anatomic constraints preclude complete resection and radiotherapy is not too toxic. Risk factors for local tumor control failure include young age, large size, presentation as recurrent disease, limb/girdle or intra-abdominal location, involved surgical margins, omission of radiotherapy, radiation dose less than 50 Gy and insufficient radiation field size. Increased comprehension of the pathogenesis and biological behavior of desmoids resulted in the emerging applicability of systemic therapies and a wait-and-see policy. Systemic treatment may be indicated in patients that have anatomic barriers to effective surgery or radiotherapy. Considering the significant morbidity of surgery and/or radiotherapy for certain locations, especially mutilation and loss of function, and the tumor's natural history, which is often characterized by prolonged periods of stability or even regression, a period of watchful waiting may compose the most appropriate management in selected asymptomatic patients. Attempts to complete eradication of the disease may be worse than the disease itself.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19374605     DOI: 10.1586/era.09.9

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  36 in total

1.  Signal transduction pathway analysis in fibromatosis: receptor and nonreceptor tyrosine kinases.

Authors:  Justin M M Cates; Jennifer O Black; Doha M Itani; John H Fasig; Vicki L Keedy; Kenneth R Hande; Brent W Whited; Kelly C Homlar; Jennifer L Halpern; Ginger E Holt; Herbert S Schwartz; Cheryl M Coffin
Journal:  Hum Pathol       Date:  2012-04-18       Impact factor: 3.466

2.  Mesenteric fibromatosis of the transverse colon with the reconstruction of the superior mesenteric arteries: report of a case.

Authors:  Makoto Seki; Rintaro Koga; Akio Saiura; Ken Nakagawa; Kazuyoshi Kawabata; Hiroaki Kanda; Mutsuo Machinami; Masaru Nakagawa
Journal:  Surg Today       Date:  2012-05-18       Impact factor: 2.549

3.  Signal transduction pathway analysis in desmoid-type fibromatosis: transforming growth factor-β, COX2 and sex steroid receptors.

Authors:  Nicholas A Mignemi; Doha M Itani; John H Fasig; Vicki L Keedy; Kenneth R Hande; Brent W Whited; Kelly C Homlar; Hernan Correa; Cheryl M Coffin; Jennifer O Black; Yajun Yi; Jennifer L Halpern; Ginger E Holt; Herbert S Schwartz; Jonathan G Schoenecker; Justin M M Cates
Journal:  Cancer Sci       Date:  2012-11-15       Impact factor: 6.716

4.  Pregnancy does not increase the local recurrence rate after surgical resection of desmoid-type fibromatosis.

Authors:  Justin M M Cates
Journal:  Int J Clin Oncol       Date:  2014-08-16       Impact factor: 3.402

5.  Primary Desmoid-Type Fibromatosis of the Mesentery: Report of an Unusual Tumor Localization.

Authors:  Mohamed Allaoui; Mohamed Tarchouli; Adil Boudhas; Reda El Ochi; Ahmed Bounaim; Abderrahmane Al Bouzidi; Mohamed Oukabli
Journal:  J Gastrointest Cancer       Date:  2018-03

6.  Activity of Sorafenib against desmoid tumor/deep fibromatosis.

Authors:  Mrinal M Gounder; Robert A Lefkowitz; Mary Louise Keohan; David R D'Adamo; Meera Hameed; Cristina R Antonescu; Samuel Singer; Katherine Stout; Linda Ahn; Robert G Maki
Journal:  Clin Cancer Res       Date:  2011-03-29       Impact factor: 12.531

7.  A 66-year-old male with lower abdominal lump: an unusual presentation of an uncommon abdominal pathology.

Authors:  Mohamed Saleem Noormohamed; Christodoulos Neophytou; Yogesh Jain; Saumitra Rawat
Journal:  BMJ Case Rep       Date:  2012-03-27

8.  Autophagy inhibition overcomes sorafenib resistance in S45F-mutated desmoid tumors.

Authors:  Danielle Braggio; David Koller; Feng Jin; Nanda Siva; Abeba Zewdu; Gonzalo Lopez; Kara Batte; Lucia Casadei; Meng Welliver; Anne M Strohecker; Dina Lev; Raphael E Pollock
Journal:  Cancer       Date:  2019-04-12       Impact factor: 6.860

9.  Mesenteric desmoid tumor developing on the site of an excised gastrointestinal stromal tumor.

Authors:  Mohammad Khan; George Bozas; Justin Cooke; Kevin Wedgwood; Anthony Maraveyas
Journal:  Rare Tumors       Date:  2010-06-30

10.  High-intensity focused ultrasound treatment for intra-abdominal desmoid tumors: a report of four cases.

Authors:  Yulan Shi; Yanqin Huang; Meiqi Zhou; Xiao Ying; Xiaoye Hu
Journal:  J Med Ultrason (2001)       Date:  2015-10-27       Impact factor: 1.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.